Anti-CYBRD1 (HPA014757) antibody for Glioma research - increased expression of CYBRD1
Article: "Highly Expressed CYBRD1 Associated with Glioma Recurrence Regulates the Immune Response of Glioma Cells to Interferon"
Glioma patients with higher CYBRD1 expression predict a poorer prognosis.
The iron reductase, cytochrome B reductase 1 (CYBRD), plays a critical role in carcinogenesis because cancer cells consume more iron than normal cells.
In patients with brain cancers, such as glioma, the increased expression of CYBRD1 is associated with aggravated clinical outcomes and recurrence of gliomas. As a result, glioma patients with higher CYBRD1 expression predict a poorer prognosis.
Our Anti-CYBRD1 (HPA014757) antibody is used in this study (2021) to visualize the CYBRD1 IHC expression in clinical glioma samples of different grades.
Read full article here.
Find out more about our polyclonal Anti-CYBRD1 (HPA014757) antibody.